Abstract
Recent studies concerning the numbers of circulating clonal B cells in patients with multiple myeloma (MM) have reported conflicting data regarding the exact level and phenotype of clonal B cells and their response to treatment. In this report we document that the peripheral blood tumor burden at presentation was reduced by induction therapy to a low level, regardless of the initial tumor burden. However, the residual clonal compartment persisted before and after transplant. The level of clonal cells showed no correlation with CD19(+) cell levels. In a single patient with MM, high numbers of phenotypically aberrant clonal cells with altered CD19 expression were identified. (Blood. 2000;96:4357-4359)
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Blood |
| Vol/bind | 96 |
| Udgave nummer | 13 |
| Sider (fra-til) | 4357-9 |
| Antal sider | 3 |
| ISSN | 0006-4971 |
| Status | Udgivet - 15 dec. 2000 |
| Udgivet eksternt | Ja |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver